The epidemiology of nonalcoholic fatty liver disease in adults

Journal of Clinical Gastroenterology

Volumn 40, Issue SUPPL. 1, 2006, Pages

  Clark, Jeanne M ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Adults; Epidemiology; Nonalcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOTENSINOGEN; ASPARTATE AMINOTRANSFERASE; CARBOHYDRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYALURONIC ACID; INSULIN; TRANSFERRIN; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BARIATRIC SURGERY; BLOOD ANALYSIS; BLOOD CHEMISTRY; BODY MASS; CANCER RISK; CAUCASIAN; CHRONIC LIVER DISEASE; CLINICAL PRACTICE; CONFERENCE PAPER; DIABETES MELLITUS; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HISPANIC; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVING DONOR; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; ORGAN DONOR; POPULATION RESEARCH; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SEX RATIO; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

CARCINOMA, HEPATOCELLULAR; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 33747517955     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000168638.84840.ff     Document Type: Conference Paper

References (68)

1. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999;29:664-669.
2. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med. 2000;108:9-13.
3. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123:134-140.
4. Ratziu V, Bonyhay L, Di MV, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology. 2002;35:1485-1493.
5. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21:3-16.
6. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438.
7. Zelman S. The liver in obesity. AMA Arch Intern Med. 1952;90:141-156.
8. Macdonald RA. Pathogenesis of nutritional cirrhosis. Arch Intern Med. 1962;110:424-434.
9. Kern WH, Heger AH, Payne JH, et al. Fatty metamorphosis of the liver in morbid obesity. Arch Pathol. 1973;96:342-346.
10. Itoh S, Tsukada Y, Motomura Y, et al. Five patients with nonalcoholic diabetic cirrhosis. Acta Hepatogastroenterol (Stuttg). 1979;26:90-97.
11. Nagore N, Scheuer PJ. The pathology of diabetic hepatitis [see comments]. J Pathol. 1988;156:155-160.
12. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221-1231.
13. Clark JM, Diehl AM. Defining nonalcoholic fatty liver disease: Implications for epidemiologic studies. Gastroenterology. 2003;124:248-250.
14. American Gastroenterological Association. Medical position statement: nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1702-1704.
15. Mosley JW, Huang W, Stram DO, et al. Donor levels of serum alanine aminotransferase activity and antibody to hepatitis B core antigen associated with recipient hepatitis C and non-B, non-C outcomes. Transfusion. 1996;36:776-781.
16. Park GJ, Lin BP, Ngu MC, et al. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol. 2000;15:386-390.
17. Yano E, Tagawa K, Yamaoka K, et al. Test validity of periodic liver function tests in a population of Japanese male bank employees. J Clin Epidemiol. 2001;54:945-951.
18. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37:1286-1292.
19. Younossi ZM, Gramlich T, Liu YC, et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol. 1998;11:560-565.
20. Ratziu V, Charlotte F, Heurtier A, et al. High sampling variability of percutaneous liver biopsy in non-alcoholic fatty livers. Hepatology. 2004;40(suppl 1):237A.
21. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960-967.
22. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease: the most common cause of abnormal liver enzymes in the U.S. population. Gastroenterology. 2001;120(suppl 1):A65.
23. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122:1649-1657.
24. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124:71-79.
25. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1-10.
26. Bellentani S, Tiribelli C, Saccoccio G, et al. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study. Hepatology. 1994;20:1442-1449.
27. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112-117.
28. Nomura H, Kashiwagi S, Hayashi J, et al. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med. 1988;27:142-149.
29. Patt CH, Yoo HY, Dibadj K, et al. Prevalence of transaminase abnormalities in asymptomatic, healthy subjects participating in an executive health-screening program. Dig Dis Sci. 2003;48:797-801.
30. Oshibuchi M, Nishi F, Sato M, et al. Frequency of abnormalities detected by abdominal ultrasound among Japanese adults. J Gastroenterol Hepatol. 1991;6:165-168.
31. Ikai E, Ishizaki M, Suzuki Y, et al. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens. 1995;9:101-105.
32. Ryan CK, Johnson LA, Germin BI, et al. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl. 2002;8:1114-1122.
33. Garcia Urena MA, Colina Ruiz-Delgado F, Moreno GE, et al. Hepatic steatosis in liver transplant donors: common feature of donor population? World J Surg. 1998;22:837-844.
34. Soejima Y, Shimada M, Suehiro T, et al. Use of steatotic graft in living-donor liver transplantation. Transplantation. 2003;76:344-348.
35. Marcos A, Fisher RA, Ham JM, et al. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation. 2000;69:2410-2415.
36. Crespo J, Fernandez-Gil P, Hernandez-Guerra M, et al. Are there predictive factors of severe liver fibrosis in morbidly obese patients with non-alcoholic steatohepatitis? Obes Surg. 2001;11:254-257.
37. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91-100.
38. Gholam PM, Kotler DP, Flancbaum LJ. Liver pathology in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg. 2002;12:49-51.
39. Poniachik J, Mancilla C, Contreras J, et al. Obesity: risk factor for steatohepatitis and hepatic fibrosis. Rev Med Chil. 2002;130:731-736.
40. Beymer C, Kowdley KV, Larson A, et al. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg. 2003;138:1240-1244.
41. Solga SF, Clark JM, Alkuraishe AR, et al. Race and co-morbid factors predict NAFLD histopathology in severely obese patients. Surg Obes Relat Dis. 2005;1:6-11.
42. Hultcrantz R, Glaumann H, Lindberg G, et al. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum amino-transferases. Scand J Gastroenterol. 1986;21:109-113.
43. Byron D, Minuk GY. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology. 1996;24:813-815.
44. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79.
45. Kojima S, Watanabe N, Numata M, et al. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol. 2003;38:954-961.
46. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med. 1997;126:137-144.
47. Falck-Ytter Y, Younossi ZM, Marchesini G, et al. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis. 2001;21:17-26.
48. Ruhl CE, Everhart JE. Epidemiology of nonalcoholic fatty liver. Clin Liver Dis. 2004;8:501-519. vii.
49. Caldwell SH, Harris DM, Patrie JT, et al. Is NASH underdiagnosed among African Americans? Am J Gastroenterol. 2002;97:1496-1500.
50. Browning JD, Kumar KS, Saboorian MH, et al. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol. 2004;99:292-298.
51. Cortez-Pinto H, Camilo ME, Baptista A, et al. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18:353-358.
52. Laine F, Bendavid C, Moirand R, et al. Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. Hepatology. 2004;39:1639-1646.
53. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356-1362.
54. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117-1123.
55. Gramlich T, Kleiner DE, McCullough AJ, et al. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol. 2004;35:196-199.
56. Dixon JB, Bhathal PS, Jonsson JR, et al. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol. 2003;39:967-971.
57. El Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol. 2001;96:2462-2467.
58. Regimbeau JM, Colombat M, Mognol P, et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl. 2004;10(suppl 1):69-73.
59. El Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460-468.
60. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625-1638.
61. Coughlin SS, Calle EE, Teras LR, et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004;159:1160-1167.
62. Friedenberg F, Pungpapong S, Zaeri N, et al. The impact of diabetes and obesity on liver histology in patients with hepatitis C. Diabetes Obes Metab. 2003;5:150-155.
63. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358-1364.
64. Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer. 2003;97:3036-3043.
65. Nair S, Mason A, Eason J, et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology. 2002;36:150-155.
66. Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714-1719.
67. Evans CD, Oien KA, MacSween RN, et al. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol. 2002;55:689-692.
68. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004;53:750-755.